Asset Details
Do you wish to reserve the book?
Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook
Do you wish to request the book?
Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook
2021
Overview
Thioredoxin-interacting protein (TXNIP), widely known as thioredoxin-binding protein 2 (TBP2), is a major binding mediator in the thioredoxin (TXN) antioxidant system, which involves a reduction-oxidation (redox) signaling complex and is pivotal for the pathophysiology of some diseases. TXNIP increases reactive oxygen species production and oxidative stress and thereby contributes to apoptosis. Recent studies indicate an evolving role of TXNIP in the pathogenesis of complex diseases such as metabolic disorders, neurological disorders, and inflammatory illnesses. In addition, TXNIP has gained significant attention due to its wide range of functions in energy metabolism, insulin sensitivity, improved insulin secretion, and also in the regulation of glucose and tumor suppressor activities in various cancers. This review aims to highlight the roles of TXNIP in the field of diabetology, neurodegenerative diseases, and inflammation. TXNIP is found to be a promising novel therapeutic target in the current review, not only in the aforementioned diseases but also in prolonged microvascular and macrovascular diseases. Therefore, TXNIP inhibitors hold promise for preventing the growing incidence of complications in relevant diseases.
Publisher
MDPI
Subject
/ Carrier Proteins - metabolism
/ Humans
/ Metabolic Syndrome - metabolism
/ Metabolic Syndrome - pathology
/ Metabolic Syndrome - therapy
/ Nervous System Diseases - metabolism
/ Nervous System Diseases - pathology
/ Nervous System Diseases - therapy
/ Nuclear Proteins - metabolism
/ Reactive Oxygen Species - metabolism
/ Review
